Neumora Therapeutics Inc. (NMRA) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Neumora Therapeutics Inc. (NASDAQ: NMRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $0.37 (-5.43% 1D, market cap $73.0M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NMRA ranks #480 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), NMRA carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CRDF (Cardiff Oncology Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $70.9M) and GRML (Greenland Mines Ltd.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $70.3M). Among the 5-stock peer group, NMRA leads on earnings multiple (N/A) while NMRA leads on capital efficiency (-35.0% ROIC).
Per NMRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001885522), Neumora Therapeutics Inc. generated $0 in revenue, $236.9M in net income, and -$206.4M in free cash flow against $191.0M in total assets and $54.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 28.8 (OVERSOLD (<32))
Capital intensity & 0% operating margin leave 16 pts on the table
While NMRA currently carries a cautious 42/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.79) and Max Pain ($0.39) forces dealer call-delta covering toward $3.83.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Neumora Therapeutics Inc. (NMRA) dropped -5.43% to $0.37, trading at 2% of its 52-week range ($0.32 – $3.65). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Gainers Neumora Therapeutics (NASDAQ:NMRA) shares rose 11.9% to $0.41 during Tuesday's after-market session. The market value of their outstanding shares is at $73.8 million. Pulmonx (NASDAQ:LUNG) stock increased
Gainers Pomdoctor (NASDAQ:POM) shares rose 25.6% to $1.47 during Friday's after-market session. The market value of their outstanding shares is at $8.3 million. GeneDx Holdings (NASDAQ:WGS) shares rose 8.72% to
Gainers Vivos Therapeutics (NASDAQ:VVOS) stock increased by 17.9% to $0.16 during Monday's after-market session. The market value of their outstanding shares is at $2.8 million. SCWorx (NASDAQ:WORX) shares moved
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on NMRA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for NMRA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Neumora Therapeutics Inc. (NMRA) ranks #480 by composite RQD confidence (42/100, grade D-) and #702 by equity capitalization ($73.0M). Within this direct 5-issuer industry benchmark cohort, NMRA leads on earnings valuation at N/A trailing P/E, while NMRA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. OKYO currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with NMRA at 42/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NMRA
ACTIVE
Neumora Therapeutics Inc. | D- | 42/100 | — | — | -35.0% | -5.43% | $73.0M | Benchmark Subject |
| CRDF Cardiff Oncology Inc. | D- | 41/100 | — | — | -35.0% | -2.46% | $70.9M | /crdf-vs-nmra → |
| GRML Greenland Mines Ltd. | E | 32/100 | — | — | -35.0% | -10.89% | $70.3M | /grml-vs-nmra → |
| CGTX Cognition Therapeutics Inc. | D- | 43/100 | — | — | -35.0% | -5.57% | $70.3M | /cgtx-vs-nmra → |
| OKYO OKYO Pharma Limited | D+ | 52/100 | — | — | — | -2.00% | $78.7M | /okyo-vs-nmra → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Neumora Therapeutics Inc. (NMRA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $236.9M, operating cash flow of -$206.4M, and free cash flow of -$206.4M (-12.8% YoY). On the balance sheet, NMRA closed FY2025 with $191.0M in total assets against $54.5M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $236.9M | -$206.4M | -$206.4M | $191.0M | $54.5M |
| FY2024 (FY) | 2024-12-31 | $0 | $243.8M | -$182.9M | -$182.9M | $317.0M | $0 |
| FY2023 (FY) | 2023-12-31 | $0 | -$235.9M | -$163.3M | -$163.3M | — | — |
As of 2026-11-02, Neumora Therapeutics Inc. (NASDAQ: NMRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $0.37 (-5.43% 1D, market cap $73.0M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NMRA ranks #480 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), NMRA carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CRDF (Cardiff Oncology Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $70.9M) and GRML (Greenland Mines Ltd.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $70.3M). Among the 5-stock peer group, NMRA leads on earnings multiple (N/A) while NMRA leads on capital efficiency (-35.0% ROIC).
Per NMRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001885522), Neumora Therapeutics Inc. generated $0 in revenue, $236.9M in net income, and -$206.4M in free cash flow against $191.0M in total assets and $54.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
NMRA last traded at $0.37 (-5.43% on volume of 1,107,541 shares), positioning the stock -53.16% below its 50-day simple moving average ($0.79) and -79.21% below its 200-day simple moving average ($1.78). Across its 52-week range of $0.32 to $3.65, NMRA sits at the 1.5% percentile with a 14-day RSI of 28.8 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.42).
Why NMRA Stock dropped -5.43% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).